Anthony Morise, MD
Cardiovascular Disease · Morgantown, WVNPI 1477667608
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Amgen at 43.8% of the total. Reporting peaked in 2019 at $120 and has fallen 72.3% since, to $33 in 2023. That places this record below the midpoint for cardiovascular disease clinicians in WV, where the typical reported total is $2,173.
Across 7 payments — averaging $30.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$94
- Regeneron Healthcare Solutions, Inc.$62
- Sanofi-aventis U.S. LLC$31
- Livanova USA, Inc.$27
Across 21 payments — averaging $4163.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$36K
- Amgen$25K
- Regeneron$22K
- Amryt Pharma Holdings Ltd$3K
- Aegerion Pharmaceuticals, Inc.$1K
What the payments were for
- Food & beverage$19692%
- Education$178%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $94 |
| Regeneron Healthcare Solutions, Inc. | 1 | $62 |
| Sanofi-aventis U.S. LLC | 1 | $31 |
| Livanova USA, Inc. | 1 | $27 |
How this compares
$213 in reported general payments places this provider in the 20th percentile of 100 cardiovascular disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 138 | $94,742 |
| Praluent PenAlirocumab | 49 | $24,282 |
| Ezetimibe | 14 | $266 |
| Rosuvastatin Calcium | 12 | $42 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Morgantown
- Partho SenguptaMorgantown$131K
- Madhavi KadiyalaMorgantown$29K
- David CampseyMorgantown$21K
- Morgan LyonsMorgantown$7K
- Muchi Ditah ChobufoMorgantown$7K
- Raahat BansalMorgantown$6K
- Walid GharibMorgantown$6K
- David TinglerMorgantown$6K
- Yasmin HamiraniMorgantown$5K
- Ruby HavistinMorgantown$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.